Overview Performance Dividends Peer Group Options

(AMRN) Amarin - Ratings and Ratios

Exchange: NASDAQ • Country: Ireland • Currency: USD • Type: Common Stock • ISIN: US0231112063

AMRN: Omega-3, Fatty Acids, Cardiovascular, Pharmaceuticals

Amarin Corporation plc (NASDAQ:AMRN) is a biopharmaceutical company focused on developing and commercializing innovative therapeutics to address cardiovascular diseases. Its lead product, VASCEPA (icosapent ethyl), is an FDA-approved prescription-only omega-3 fatty acid medication designed to reduce triglyceride levels in adults with severe hypertriglyceridemia. The drug has also gained approval for reducing cardiovascular risk in certain high-risk patients. Amarin operates primarily in the U.S., Europe, Canada, Lebanon, and the United Arab Emirates, distributing its products through wholesalers and specialty pharmacy providers. The company collaborates with Mochida Pharmaceutical Co., Ltd. to expand its product portfolio and indications. Originally incorporated in 1989 as Ethical Holdings plc, Amarin rebranded in 1999 and is headquartered in Dublin, Ireland.

Based on the current technical indicators, AMRN is trading below its 20-day and 50-day simple moving averages (SMA), which are at 0.57 and 0.54 respectively, while the 200-day SMA stands at 0.62. The stock is showing signs of short-term weakness, with the average trading volume of 910,989 shares over the past 20 days. The ATR of 0.04 indicates low volatility, suggesting that price movements are likely to remain tight in the near term. From a fundamental perspective, Amarins market cap is $242.32 million, with a forward P/E ratio of 500.00, reflecting high expectations for future earnings despite current losses (RoE: -7.41). The P/S ratio of 1.01 indicates moderate valuation relative to its revenue. Over the next three months, the stock is likely to face resistance at the 200-day SMA of 0.62 and support at the 50-day SMA of 0.54. The low ATR suggests limited price fluctuations, but the negative return on equity and high forward P/E ratio may weigh on investor sentiment.

Additional Sources for AMRN Stock

News: Wall Street Journal Benzinga Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

AMRN Stock Overview

Market Cap in USD 223m
Sector Healthcare
Industry Drug Manufacturers - General
GiC Sub-Industry Biotechnology
IPO / Inception 1993-04-01

AMRN Stock Ratings

Growth Rating -94.5
Fundamental -50.9
Dividend Rating 0.0
Rel. Strength -31.2
Analysts 2.33/5
Fair Price Momentum 5.51 USD
Fair Price DCF -

AMRN Dividends

No Dividends Paid

AMRN Growth Ratios

Growth Correlation 3m -27.2%
Growth Correlation 12m -85.8%
Growth Correlation 5y -96%
CAGR 5y -41.89%
CAGR/Max DD 5y -0.44
Sharpe Ratio 12m -1.09
Alpha -52.46
Beta 1.306
Volatility 65.35%
Current Volume 85.4k
Average Volume 20d 86k
What is the price of AMRN stocks?
As of May 10, 2025, the stock is trading at USD 10.41 with a total of 85,421 shares traded.
Over the past week, the price has changed by -4.58%, over one month by +13.57%, over three months by -0.55% and over the past year by -40.85%.
Is Amarin a good stock to buy?
No, based on ValueRay Fundamental Analyses, Amarin (NASDAQ:AMRN) is currently (May 2025) a stock to sell. It has a ValueRay Fundamental Rating of -50.90 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AMRN as of May 2025 is 5.51. This means that AMRN is currently overvalued and has a potential downside of -47.07%.
Is AMRN a buy, sell or hold?
Amarin has received a consensus analysts rating of 2.33. Therefor, it is recommend to sell AMRN.
  • Strong Buy: 0
  • Buy: 0
  • Hold: 1
  • Sell: 2
  • Strong Sell: 0
What are the forecast for AMRN stock price target?
According to ValueRays Forecast Model, AMRN Amarin will be worth about 6.3 in May 2026. The stock is currently trading at 10.41. This means that the stock has a potential downside of -39.1%.
Issuer Forecast Upside
Wallstreet Target Price 13.5 29.7%
Analysts Target Price 13.5 29.7%
ValueRay Target Price 6.3 -39.1%